With more than 15 years of experience in the field of oncology, Dr. Arun Krishna has witnessed firsthand the progress in the lung cancer space. Today, he serves as Vice President and Head of Lung Cancer Franchise at AstraZeneca’s U.S. Oncology Business Unit.

While the statistics point to a promising trend, Arun is cognizant of the fact that there is much more work to be done. This is why AstraZeneca set up the Lung Ambition Alliance (LAA) a few years ago – to bring together stakeholders across the healthcare landscape to connect patients to early diagnosis and treatment processes.

In this episode, Julia Douthart sits down with Arun to discuss the work of the LAA, as well as what motivates him to work on a daily basis. 

With more than 15 years of experience in the field of oncology, Dr. Arun Krishna has witnessed firsthand the progress in the lung cancer space. Today, he serves as Vice President and Head of Lung Cancer Franchise at AstraZeneca’s U.S. Oncology Business Unit.
While the statistics point to a promising trend, Arun is cognizant of the fact that there is much more work to be done. This is why AstraZeneca set up the Lung Ambition Alliance (LAA) a few years ago – to bring together stakeholders across the healthcare landscape to connect patients to early diagnosis and treatment processes.
In this episode, Julia Douthart sits down with Arun to discuss the work of the LAA, as well as what motivates him to work on a daily basis.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;